Your Article Summary
See Latest ArticlesMultipotent mesenchymal stromal cells and rheumatoid arthritis: Risk or benefit?
Rheumatology, 07/01/09
Bouffi C et al. – Review discusses the new potential therapeutic applications of mesenchymal stromal cells (MSC)-based therapy in osteo-articular diseases, and also assesses the potential risks associated with it.
- MSCs play a dual role that may be of benefit in RA owing to their immunosuppressive properties and their potential of differentiation towards chondrocytes
- MSC-based cartilage engineering is a promising approach in case of cartilage injury
- It must be underlined that in case of chronic inflammation, the differentiation ability of MSCs is inhibited
- MSCs exert their immunosuppressive effect after activation by pro-inflammatory cytokines such as IFN-γ and IL-1β, secreted in arthritic joints
- Indeed, the local inflammation may be important for MSCs to display their therapeutic efficacy in RA
- An in vitro step of pre-conditioning of MSCs may also be required to more efficiently trigger the immunomodulatory potential of MSCs
- In conclusion, stromal cells appear as major regulatory cells in skeletal tissue homeostasis, controlling inflammation, immune response, fibrosis and tissue regeneration
Related Articles
Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: A 3-month, randomized, double-blind, placebo-controlled trial
Clinical Therapeutics, 10/15/09
Relevance Score: 71%
Certolizumab Pegol: In Rheumatoid Arthritis
BioDrugs, 11/11/09
Relevance Score: 70%
Assistive technology for rheumatoid arthritis
Cochrane Reviews, 10/09/09
Relevance Score: 70%
Treatment of early RA with infliximab is beneficial
American Pharmacists Association, 11/06/09
Relevance Score: 69%
Abatacept for rheumatoid arthritis
Cochrane Reviews, 10/09/09
Relevance Score: 69%
Today in Rheumatoid Arthritis...keeping you current
Receive free subspecialty "5-minute updates" via email
Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study
Arthritis Research & Therapy, 12/19/09
Update on the genetic risk factors for rheumatoid arthritis
Expert Review of Clinical Immunology, 12/18/09
The diagnostic utilities of anti-agalactosyl IgG antibodies, anti-cyclic citrullinated peptide antibodies, and rheumatoid factors in rheumatoid arthritis
Rheumatology International, 12/18/09